Business
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
Year-over-year revenue increased 70%, reflecting contribution from Vivos’ acquisition of The Sleep Center of Nevada Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today
About this update from Vivos Therapeutics, Inc.
[{"type":"image","alt":"Vivos Therapeutics, Inc","displaySize":"","headline":null,"caption":"Vivos Therapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":148,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/452f3e3cd3796a0ed8557400112a2519"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5XWT0BIbkgsMnIYiOrlVPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTY1/https://media.zenfs.com/en/globenewswire.com/452f3e3cd3796a0ed8557400112a2519","width":148,"height":46},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/5XWT0BIbkgsMnIYiOrlVPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTY1/https://media.zenfs.com/en/globenewswire.com/452f3e3cd3796a0ed8557400112a2519","width":148,"height":46}},"lazy":false},{"type":"text","content":"Year-over-year revenue increased 70%, reflecting contribution from Vivos’ acquisition of The Sleep Center of Nevada","length":115,"tagName":"p"},{"type":"text","content":"Management to Host Conference Call today at 5:00 pm ET","length":54,"tagName":"p"},{"type":"text","content":"LITTLETON, Colo., May 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today reported financial results and operating highlights for the first quarter ended March 31, 2026.","length":425,"tagName":"p"},{"type":"text","content":"Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, stated “Our significant revenue increase year over year and quarter over quarter confirms what we emphatically stated when we reported our 2025 year end results last month: that the fourth quarter of 2025 was not fully indicative of our overall growth trajectory, which remains strong and is accelerating here in the second quarter. Our June 2025 acquisition of SCN and business model pivot continues to drive patient volume and top-line revenue, and we are working hard to increase the daily productivity of SCN doctors and insurance reimbursement. Importantly, and as expected, we are seeing a very significant reduction in customer acquisition costs. So, our goal is continued integration of, and growth from, SCN and other medical provider collaborations, and our current results demonstrate that this...